Neurotoxicity of ␤-amyloid peptide (A␤) in Alzheimer's disease (AD) is usually thought to arise from the nonspecific effects of high concentrations of A␤ on vunerable neurons, resulting in membrane destabilization and increasing intracellular calcium concentration. This review advances the hypothesis that at early stages of AD, when A␤ is present in lower amounts, its ability to perturb the function of cellular targets is mediated by specific cofactors present on the cell surface and intracellularly. Receptor for advanced glycation endproducts (RAGE) is a cell-surface receptor which binds A␤ and amplifies its effects on cells in the nanomolar range. The intracellular enzyme A␤-binding alcohol dehydrogenase (ABAD) is likely to engage nascent A␤ formed in the endoplasmic reticulum, and to mediate cell stress from this site. The analysis of A␤ interaction with RAGE and ABAD, as well as other cofactors, provides insight into new mechanisms and, potentially, identifies therapeutic targets relevent to neuronal dysfunction in AD.
Introduction
Extracellular accumulations of amyloid in neuritic plaques, composed predominately of ␤-amyloid (A␤) peptide and intracellular neurofibrillary tangles, composed in large part of hyperphosphorylated paired helical filament tau, are pathognomonic features of Alzheimer's disease (AD) [1] [2] [3] [4] [5] . With time, these lesions increase in number and volume, concomitant with neuronal toxicity and death [1] [2] [3] [4] [5] [6] . While amyloidogenic peptides are condensed into copious fibrillar deposits in the middle to late stages of AD, the relationship of such lesions to mechanisms of early cellular dysfunction is undefined. It is possible that the densely packed deposits of A␤ found at the centre of neuritic plaques Biochem. Soc. Symp. 67, [15] [16] [17] [18] [19] [20] [21] [22] (Printed in Great Britain) 15 2 1 To whom correspondence should be addressed.
may have a protective function by sequestering toxic amyloid from cellular elements.
A␤ interaction with cell surface receptors
In AD it is widely accepted that later in the course of the disease, when A␤ fibrils are abundant, non-specific interactions of such fibrils with the cell surface may be frequent and disruptive for cellular functions [7] [8] [9] [10] [11] [12] (Figure 1,  left) . A␤ fibrils can destroy plasma membranes, causing changes in ionic homoeostasis, and could trigger cell death by several mechanisms. However, earlier in the course of the disease when A␤ fibrils are present at lower levels, and A␤ is presumably present principally in oligomeric soluble forms, higher affinity interactions with cellular surface molecules are more likely to be relevant (Figure 1, right) . One such molecule is the immunoglobulin superfamily receptor RAGE (receptor for advanced glycation endproducts). In the AD brain, this receptor is expressed at higher levels in neurons and microglia proximate to neuritic plaques and in cells of A␤-loaded blood vessels, than in those areas free of pathology or in control brains [13] . RAGE binds A␤ in its soluble monomeric/oligomeric and insoluble fibrillar forms with nanomolar affinity, targeting the amyloidogenic peptide to the cell surface. In culture, cells expressing RAGE are more susceptible to A␤-induced cellular dysfunction than those with lower levels of RAGE, or those in which the receptor is blocked. [Ca] i ROI other Consistent with a role for A␤-receptor interactions in the early disruption of neuronal functions, are the findings that A␤ binding to neuronal RAGE results in activation of nuclear factor B (NF-B), induction of haem oxygenase type 1 and expression of macrophage-colony stimulating factor (M-CSF), each of which can be demonstrated in AD brain [13, 14] . In contrast, cells expressing low levels of RAGE require greater concentrations of A␤ to bring about changes in cellular properties. Cellular disruption resulting from low levels of A␤ binding to RAGE reflects active redirection of cellular biosynthetic mechanisms, not non-specific and rapid induction of cell death, which is observed at high levels of A␤ (the latter is independent of RAGE). Therefore, A␤-RAGE interaction could contribute to the well-recognized chronic inflammatory component underlying AD. A␤ stimulation of RAGE causes nuclear translocation of NF-B, thereby increasing the expression of M-CSF by neurons (which also spills over into cerebrospinal fluid) and resulting in the recruitment and activation of microglia to early sites of cellular disruption [14] (Figure 2 ). In view of the multiple conformational structures into which A␤ assembles, it is to be expected that the amyloidogenic peptide will interact with several cell-surface recognition sites, potentially opportunistic receptors whose activation could engender varied alterations in cellular phenotype. Consistent with this theory, the macrophage scavenger receptor, expressed selectively in the brain on microglia, has been shown to bind and internalize A␤ fibrils [15, 16] . Such endocytosis of A␤ could enhance a protective function, by sequestering and disposing of toxic peptides, or alternatively could contribute to pathogenicity by promoting chronic cellular dysfunction. In this context, increased expression of megalin/gp330, a lipoprotein receptor that serves as an acceptor site for apolipoprotein E (ApoE) [17] , in neurons that display intracellular ApoE and A␤ as well as evidence of DNA fragmentation suggests that uptake of the ApoE/A␤ complex via this receptor system may load cells with intracellular A␤ in a relatively stable complex that promotes toxicity, and eventually apoptosis [17] . Although cell-surface RAGE [18] , and presumably other A␤ cellular binding sites, are not necessary or even sufficient mediators of A␤-induced cytotoxicity (which can occur in the absence of RAGE given a sufficiently high concentration of A␤), the presence of such receptors may serve to focus and amplify the toxic effects of A␤, especially at relatively low amounts of peptide and when A␤ is in filamentous form. If only by sustained approximation of A␤ to the cell surface, RAGE can effectively increase toxicity but, in addition, binding of A␤ to RAGE may trigger intracellular signals deleterious to cell function and viability. Finally, RAGE can also serve to assist clearance of very small amounts of A␤ (or filaments) through interaction of the A␤-RAGE complex. The ability of RAGE to bind A␤ and advanced glycation endproducts (AGEs) [19] is in all likelihood an accident of evolution due to molecular mimicry with other RAGE ligands such as amphoterin [20] , which promotes neurite outgrowth in the developing brain. A result of the proposed involvement of A␤ receptors in the pathogenesis of AD is that early in the course of this disorder, before irreversible cellular events occur, inhibition of A␤-cell-surface interactions could be neuroprotective, and potentially therapeutic. However, this hypothesis must await development of appropriate transgenic animal models that imitate the pathophysiology of AD to be proved completely. In this context, mice overexpressing RAGE and/or the scavenger receptor, along with other susceptibility factors such as presenilins or ␤-amyloid precursor protein (APP) mutants, may represent excellent candidates for such models.
A␤ interaction with the intracellular enzyme ABAD (A␤-binding alcohol dehydrogenase)
Evidence linking increased production of A␤, in culture and in the brains of transgenic mice that are overexpressing presenilins or which have mutations in APP, with early-onset familial AD have highlighted a role for A␤ in the pathogenesis of neurodegeneration [1] [2] [3] [21] [22] [23] [24] . Processing of APP may occur by several pathways [1] , including generation of the amyloidogenic peptide within the endoplasmic reticulum [25] [26] [27] [28] , also a site for localization of presenilin [29] . Immunoprecipitation of APP-presenilin complexes formed within the cell indicates that these two molecules may interact in vivo, potentially affecting the processing of APP [30] . Using the yeast two-hybrid system, we have identified a polypeptide, ABAD, which specifically binds A␤. ABAD was found in the endoplasmic reticulum and in mitochondria and was originally named ERAB (endoplasmic reticulum-associated A␤ binding protein), after its first site of intracellular localization within the endoplasmic reticulum. However, it is now refered to as ABAD in view of its functional properties and presence in multiple subcellular compartments [31] . ABAD binds with nanomolar affinity to the A␤ monomer/oligomer, as well as to A␤ assembled into fibrils, and it potentiates A␤-induced cellular toxicity, assessed by induction of apoptosis. The blockage of ABAD-A␤ interaction, through the intro-duction of anti-ABAD F(abЈ) 2 into cells, using liposomes, suppressed A␤-induced apoptosis at lower concentrations of amyloidogenic peptide (up to 1 M). However, at higher concentrations of A␤ (Ͻ 10 M), the effects of ABAD were not discernible, presumably due to an excess of non-specific A␤-cellular interactions. Immunohistochemical analysis of the AD brain shows ABAD at low levels in normal cortical neurons, but with substantially increased expression in AD neurons in the brains of patients with AD. ABAD is an intriguing cellular target of A␤ as it is the human counterpart of type II 3-hydroxyacyl-CoA dehydrogenase, an enzyme which participates in the third reaction of the ␤-oxidation spiral [32] , and is therefore integral to cellular energy and fatty acid metabolism. Based on protein sequence homologies, ABAD could also be a short chain-alcohol dehydrogenase, which suggests its potential to generate toxic aldehydes within disrupted cells. Of course, the discovery of ABAD raises many questions with respect to how such an intracellular polypeptide gains access to A␤, whether ABAD enzymic activity is related to its potential role in cellular toxicity, and, if this is not the case, whether its activity is modulated by A␤. These considerations indicate the extent to which further studies will be required to determine a possible role for ABAD in A␤-mediated neurotoxicity. In this context, it is possible that intracellular A␤, concentrated in cellular compartments such as the endoplasmic reticulum and Golgi or in the endosomal-lysosomal pathway, damages cell membranes and gains access to otherwise remote subcellular targets [33] . Other neurotoxic species also interact with enzymes fundamental in cellular metabolism, as illustrated by the binding of huntingtin and other proteins containing polyglutamine domains to glyceraldehyde-3-phosphate dehydrogenase [34] [35] [36] . The potential of A␤, an enzyme that can participate in cellular homoeostasis, to modulate properties of an intracellular target ( Figure 3 
Conclusion
There is still much unknown about the pathogenesis and even pathological manifestations of sporadic AD. This is exemplified by the recent recognition of distinct hitherto unsuspected extracellular proteinaceous deposits of ~100 kDa polypeptide in AD with monoclonal antibodies to plaque-derived substances [37] . The identification and characterization of specific cellular targets of A␤, such as RAGE, scavenger receptor, megalin/gp330 and ABAD provides a context for considering early cellular perturbations due to A␤, in relation to both cell-surface binding sites/receptors and intracellular targets, and may provide new insights into molecular mechanisms and future therapeutic approaches.
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